Regeneron Locks Co-Founders Into A Decade Of Performance Targets — No New Equity Until 2036
A one-time grant of up to 5.6 million performance share units ties CEO Leonard Schleifer and CSO George Yancopoulos to a $30 billion revenue target.
Regeneron's board granted its two co-founder executives a sweeping, all-or-nothing equity package on Thursday that replaces every annual equity award they would otherwise receive through 2036, according to an 8-K filed Wednesday with the SEC. The performance share units — capped at 2,700,000 for CEO Leonard Schleifer and 2,900,000 for Chief Scientific Officer George Yancopoulos — pay out only if the company hits a set of pipeline and revenue milestones over the next decade, with the top earnout requiring nearly $30 billion in annual revenues from new products.
What The Filing Says
The Compensation Committee granted the awards effective Thursday, September 24, acting with approval from the independent, non-employee members of the board. The grants are structured entirely as performance share units — no time-based equity, no guaranteed payout — and the shares cannot be sold until February 2036, when 2035 performance is certified. Exceptions apply only for death, disability, or a change in control.
Performance goals fall into two buckets, as described in the supplemental exhibit filed alongside the 8-K. The smaller opportunity is tied to pipeline activity: each new drug application or biologics license application filed with the FDA from January 1, 2026 through December 31, 2034 earns 10,000 units per executive; each FDA approval of a new product filing earns 15,000 units; and each qualifying supplemental approval that expands an eligible patient population earns 12,500 units.
The larger opportunity — and the one that drives the bulk of potential earnout — is revenue. No revenue-based units are earned below $10 billion in annual sales from newly approved or acquired products. At exactly $10 billion, each executive earns 250,000 units, scaling linearly to 900,000 units at $18 billion and 1,800,000 units at $30 billion. The $30 billion threshold is roughly double Regeneron's total 2025 revenues, a bar the board acknowledged requires exceptional execution against rising biosimilar and branded competition.
For acquired products, only sales above the pre-acquisition baseline count. Two products — Lynozyfic (linvoseltamab) and Otarmeni (lunsotogene parvec) — are included in the new-product definition only if Regeneron obtains significant label expansions for them during the performance period.
A relative total shareholder return modifier adjusts the final earnout by up to plus or minus 20%, measured against the NASDAQ Biotechnology Total Return Index over the full ten years. Any shares delivered before the performance period ends carry a 20% holdback pending that final adjustment in 2036. An alternative path to the absolute cap exists: generating $40 billion in combined new-product revenues in 2034 and 2035 together with positive absolute total shareholder return that exceeds the NASDAQ Biotechnology Total Return Index.
Below the revenue threshold, activity-based earnout is capped at 100,000 units for Schleifer and 300,000 units for Yancopoulos — the higher CSO limit reflecting his primary responsibility for the research and development work that generates pipeline milestones. Between $10 billion and $30 billion in revenues, activity-based units may not exceed 30% of the total earned by both executives combined.
The Rationale — And The Stakes For Holders
The board's case for the structure rests on Regeneron's track record and the scale of what comes next. The filing cites nearly 40 years of leadership by Schleifer and Yancopoulos, during which the company invented, developed, and commercialized 16 approved or authorized medicines. Four of those have reached blockbuster status, each generating more than $1 billion in annual net product sales. Total shareholder return since the company went public stands at more than 3,500%.
Looking forward, the board pointed to a pipeline of roughly 50 product candidates as the foundation for the growth strategy the new awards are designed to incentivize. The award structure emerged from a multi-year process led by the Compensation Committee, which ran a dedicated 2026 engagement campaign — led by the independent Compensation Committee Chair and Lead Independent Director — to gather direct input from the company's largest investors. Consistent with that feedback, the final design weights revenue generation far more heavily than pipeline activity alone.
For existing holders, the structure has two notable mechanical effects. First, the awards replace all annual equity grants for both executives through 2036, which removes a recurring source of dilution from the annual grant cycle. Second, the earnout is heavily back-loaded: no revenue-based units can be certified before fiscal year 2032 results are in, activity-based earnout is capped through 2031, and aggregate earnout is capped through 2033, with further delivery limits applying before 2035. The earliest meaningful revenue-based certification is therefore following fiscal year 2032.
The awards also require both executives to participate in good-faith CEO and CSO succession planning, with formal plans due by the fifth anniversary of the grant date. Voluntary departure or retirement before the applicable earnout measurement dates results in full forfeiture of any unvested units. Service as a board member satisfies the continuous-service requirement, and both executives retain the right to be nominated as board members for as long as they remain employed as CEO and CSO.
Regarding the subsidiary disclosure in the same filing: the 8-K also notes that Regeneron recently formed a new entity to explore a potential non-core business opportunity, with both Schleifer and Yancopoulos receiving a partially vesting equity stake. The company described the subsidiary as majority-owned and controlled by Regeneron, with nominal value, no significant assets, and no operations commenced — and said it may not pursue the opportunity at all.
What To Watch
The first real test of whether the awards will pay out at all comes at the end of fiscal year 2032, when the Compensation Committee can first certify revenue-based earnout. Between now and then, the pipeline-activity metrics — new drug filings and FDA approvals — will accumulate, but their earnout is capped and secondary to the revenue goals.
The $10 billion annual revenue threshold from new products is the floor that unlocks the revenue-based units entirely. Whether Regeneron can advance enough of its roughly 50 pipeline candidates to generate that level of sales from newly approved medicines by 2032 or 2033 will be the central question investors track against this award structure for years.
Regenereon shares closed at $758.27 on Wednesday, up about 1%, though the 8-K was accepted after the market closed and the move predates the disclosure (market data).
The awards run through December 31, 2035, with final certification and the lifting of mandatory holding restrictions scheduled for February 2036.
